DadFinStart your free week
DadFin › Stocks › Healthcare › CRDL

Cardiol Therapeutics Inc. (CRDL) stock score

Healthcare · Drug Manufacturers - Specialty & Generic · Canada

$1.23 ▼ -5.38% today

26.7
Dad Score, out of 100
weak

Cardiol Therapeutics Inc. (CRDL) is a Drug Manufacturers - Specialty & Generic company in the Healthcare sector, listed in Canada. On DadFin's weekly run it scores 26.7 out of 100 on the Dad Score, a weak reading that places the business ahead of 27% of the 5,774 US and Canadian stocks DadFin fully scores. Inside Healthcare it ranks #667 of 974. Its strongest axes are risk and conviction; its weakest are quality and price action.

Scores from the run of Oct 4, 2026. The Dad Score answers one question: how good is this business, measured against its own sector. How it is built →

The eight axes

Valuation
Average
Quality
Weak
Growth
Average
Price action
Below average
Risk
Above average
Conviction
Above average
Liquidity
Below average
Macro
Average

Each axis is ranked inside the stock's own sector. Subscribers see the percentile and every input behind each bar.

Key numbers

P/E (trailing)0.0×
P/E (forward)-6.1×
Dividend yield0.00%
Return on capital-188.2%
Operating margin0.0%
Revenue growth (YoY)+0.0%
FCF yield-15.9%
Net debt / EBITDA3.00×
Piotroski F-Score1 / 9
52-week change+30.6%
Market cap$171M
Next earningsNov 12, 2026

What subscribers see on CRDL

Start your free weekSubscriber? Open the full research →

Drug Manufacturers - Specialty & Generic peers

StockCompanyDad ScoreBandMarket cap
TAKTakeda Pharmaceutical Company Limi32.9weak$57.1B
TEVATeva Pharmaceutical Industries Lim93.6strong$46.1B
HLNHaleon plc64.5middling$38.7B
ZTSZoetis Inc.61.2middling$28.8B
UTHRUnited Therapeutics Corporation99.8strong$23.2B
VTRSViatris Inc.54.4middling$20.2B
NBIXNeurocrine Biosciences, Inc.98.4strong$14.6B
ELANElanco Animal Health Incorporated84.0good$11.1B

Prices from DadFin's live feed (refreshed about every 15 minutes in the session); scores from the weekly run of Oct 4, 2026. Fundamentals as reported in the latest filings. Research, not investment advice.